지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.9
- 수록면
- 154 - 160 (7page)
이용수
초록· 키워드
오류제보하기
Objectives：The purpose of this study was to investigate clinical characteristics of children and adolescents with autism spectrum disorders (ASDs) using methylphenidate (MPH).
Methods：Retrospective review of the charts of 79 children and adolescents with ASDs, who visited the Department of Child and Adolescent Psychiatry of Seoul National Hospital, from July 2010 to July 2011, was conducted. Changes in illness severity and improvement were measured using the Clinical Global Impression-Severity of illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scales.
Results：We found that MPH was prescribed in 23 (29.1%) children and adolescents. Of the 23 patients on MPH, 4 patients (17.4%) were on MPH monotherapy and 18 patients (78.3%) were using risperidone concomitantly. MPH was prescribed primarily for symptoms of hyperactivity and impulsivity in ASDs patients. The mean dosage of MPH was 26.2±11.1㎎g/day and mean duration of treatment was 31.9±28.7 months. Mean CGI-S score improved significantly from baseline to endpoint (from 5.4±0.6 to 4.1±0.9 ; p＜.01). MPH was reported to be effective in 17 patients (17/23, 73.9%), and 10 patients (10/23, 43.5%) reported side effects. Side effects included decreased appetite (4/23, 17.4%), tic (2/23, 8.6%), sleep disturbances (2/23, 8.6%), headache (1/23, 4.3%) and irritability (1/23, 4.3%).
Conclusion：The results of this study demonstrate that MPH may be used effectively and safely in children and adolescents with ASDs with hyperactivity and impulsivity. Future controlled trials are needed to confirm these findings.
Methods：Retrospective review of the charts of 79 children and adolescents with ASDs, who visited the Department of Child and Adolescent Psychiatry of Seoul National Hospital, from July 2010 to July 2011, was conducted. Changes in illness severity and improvement were measured using the Clinical Global Impression-Severity of illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scales.
Results：We found that MPH was prescribed in 23 (29.1%) children and adolescents. Of the 23 patients on MPH, 4 patients (17.4%) were on MPH monotherapy and 18 patients (78.3%) were using risperidone concomitantly. MPH was prescribed primarily for symptoms of hyperactivity and impulsivity in ASDs patients. The mean dosage of MPH was 26.2±11.1㎎g/day and mean duration of treatment was 31.9±28.7 months. Mean CGI-S score improved significantly from baseline to endpoint (from 5.4±0.6 to 4.1±0.9 ; p＜.01). MPH was reported to be effective in 17 patients (17/23, 73.9%), and 10 patients (10/23, 43.5%) reported side effects. Side effects included decreased appetite (4/23, 17.4%), tic (2/23, 8.6%), sleep disturbances (2/23, 8.6%), headache (1/23, 4.3%) and irritability (1/23, 4.3%).
Conclusion：The results of this study demonstrate that MPH may be used effectively and safely in children and adolescents with ASDs with hyperactivity and impulsivity. Future controlled trials are needed to confirm these findings.
목차
서론
방법
결과
고찰
결론
References
참고문헌 (25)
참고문헌 신청
1. [단행본] - American Psychiatric Association. / 2000 / Diagnostic and Statistical Manual of Mental Disorders IV-Text Revision / American Psychiatric Association
2. [학술지(정기간행물)] - Nazeer A, Ghaziuddin M / 2012 / Autism spectrum disorders: clinical features and diagnosis / Pediatr Clin North Am 59 : 19 ~ 25
3. [학술지(정기간행물)] - Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention / 2012 / Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008 / MMWR Surveill Summ 61 : 1 ~ 19
4. [학술지(정기간행물)] - Kim YS / 2011 / Prevalence of autism spectrum disorders in a total population sample / Am J Psychiatry 168 : 904 ~ 912
5. [단행본] - Hillman J / 2007 / Childhood Autism / Taylor & Francis Group : 49 ~
2. [학술지(정기간행물)] - Nazeer A, Ghaziuddin M / 2012 / Autism spectrum disorders: clinical features and diagnosis / Pediatr Clin North Am 59 : 19 ~ 25
3. [학술지(정기간행물)] - Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention / 2012 / Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008 / MMWR Surveill Summ 61 : 1 ~ 19
4. [학술지(정기간행물)] - Kim YS / 2011 / Prevalence of autism spectrum disorders in a total population sample / Am J Psychiatry 168 : 904 ~ 912
5. [단행본] - Hillman J / 2007 / Childhood Autism / Taylor & Francis Group : 49 ~
이 논문의 저자 정보
이 논문과 함께 이용한 논문
자폐 청소년 장애학생에 대한 연구동향과 과제 : 최근 10년간 국내 연구를 중심으로
강혜경
특수교육
2012
.10
자폐스펙트럼 장애아동의 의사소통 기술 향상에 관한 단일대상연구의 문헌 분석
정유진
,
윤현숙
특수교육
2014
.02
자폐 스펙트럼장애의 환경 요인
임명호
,
권호장
소아청소년정신의학
2011
.03
자폐스펙트럼장애에서 나타나는 퇴행의 임상적인 특징
김지순
,
유희정
,
조인희
외 10명
소아청소년정신의학
2011
.09
자폐 범주성 장애 아동에서 아동ㆍ청소년 행동평가척도의 요인분석
박은영
한국콘텐츠학회논문지
2011
.08
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-516-000731533